Wall Street Zen Upgrades Immunovant (NASDAQ:IMVT) to “Hold”

Immunovant (NASDAQ:IMVT – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

Several other equities analysts have also recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Immunovant in a research report on Tuesday, August 25th. Truist Financial upped their price target on shares of Immunovant from $30.00 to $33.00 and gave the stock a “hold” rating in a report on Tuesday, November 10th. Citigroup reiterated a “positive” rating on shares of Immunovant in a research report on Thursday, September 24th. HC Wainwright reiterated a “buy” rating on shares of Immunovant in a research report on Thursday, September 24th. Finally, Wells Fargo & Company lifted their price objective on shares of Immunovant from $45.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, November 10th. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $44.60.

Check Out Our Latest Analysis on Immunovant

Immunovant Price Performance

IMVT stock opened at $34.18 on Friday. The company has a market cap of $7.07 billion, a PE ratio of -13.35 and a beta of 0.95. The business has a 50-day simple moving average of $32.64 and a 200 day simple moving average of $32.33. Immunovant has a 52 week low of $21.86 and a 52 week high of $45.42.

Immunovant (NASDAQ:IMVT – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.27. During the same quarter in the prior year, the firm posted ($0.73) EPS. On average, analysts anticipate that Immunovant will post -2.78 EPS for the current fiscal year.

Insider Activity

In other news, COO Melanie Gloria sold 2,241 shares of Immunovant stock in a transaction dated Wednesday, October 7th. The stock was sold at an average price of $32.06, for a total transaction of $71,846.46. Following the sale, the chief operating officer directly owned 217,060 shares of the company’s stock, valued at approximately $6,958,943.60. This trade represents a 1.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Christopher Van Tuyl sold 1,327 shares of the business’s stock in a transaction dated Wednesday, October 7th. The stock was sold at an average price of $32.06, for a total value of $42,543.62. Following the sale, the insider owned 175,218 shares in the company, valued at approximately $5,617,489.08. This trade represents a 0.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 27,430 shares of company stock valued at $895,852. 1.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Immunovant

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in Immunovant during the 2nd quarter worth about $276,680,000. Two Seas Capital LP bought a new stake in shares of Immunovant in the 2nd quarter valued at about $121,312,000. Jennison Associates LLC grew its position in shares of Immunovant by 356.4% in the 1st quarter. Jennison Associates LLC now owns 3,196,705 shares of the company’s stock valued at $79,406,000 after buying an additional 2,496,241 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of Immunovant in the second quarter valued at about $89,802,000. Finally, Bank of America Corp DE acquired a new stake in shares of Immunovant in the second quarter valued at about $45,521,000. 47.08% of the stock is currently owned by institutional investors and hedge funds.

About Immunovant

(Get Free Report)

Immunovant, Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies. The company’s investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves’ disease and other autoimmune disorders.

Further Reading

Analyst Recommendations for Immunovant (NASDAQ:IMVT)

Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.